December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

35.28 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Earnings Outlook For Harmony Biosciences ↗
 
Via Benzinga
News headline image
Breaking Down Harmony Biosciences: 6 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says ↗
UBS has initiated coverage on Harmony Biosciences with a Buy rating and a price target of $56. UBS highlights Harmony's potential for growth, projecting a 19% CAGR for Wakix sales through 2026. 
Via Benzinga
News headline image
Unveiling 6 Analyst Insights On Harmony Biosciences ↗
 
Via Benzinga
News headline image
Harmony Biosciences (HRMY) Q2 2024 Earnings Call Transcript ↗
HRMY earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Analyst Expectations For Harmony Biosciences's Future ↗
 
Via Benzinga
News headline image
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Beats Revenue for Q2 2024 ↗
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts ↗
 
Via Benzinga
News headline image
Key Takeaways From Harmony Biosciences Analyst Ratings ↗
 
Via Benzinga
News headline image
Evaluating Harmony Biosciences: Insights From 8 Financial Analysts ↗
 
Via Benzinga
News headline image
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
From Harmony Biosciences
Via GlobeNewswire
News headline image
7 Cheap Biotech Stocks With Major Upside Potential ↗
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks. 
Via InvestorPlace
News headline image
7 Undervalued Biotech Stocks to Buy for Big-Time Returns ↗
The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive. 
Via InvestorPlace
News headline image
7 Biotech Stocks to Buy on the Dip: June 2024 ↗
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
News headline image
Analyst Ratings For Harmony Biosciences ↗
 
Via Benzinga
News headline image
NASDAQ:HRMY stands out as a growth opportunity that won't break the bank. ↗
Looking for growth without the hefty price tag? Consider NASDAQ:HRMY. 
Via Chartmill
News headline image
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 6 Analysts ↗
 
Via Benzinga
News headline image
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In ↗
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. 
Via Benzinga
Topics Cannabis
News headline image
Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript ↗
HRMY earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024 ↗
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View ↗
Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epilepsy offerings. Harmony's Q1 performance shows robust growth, with... 
Via Benzinga
Topics Earnings
News headline image
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
From Harmony Biosciences
Via GlobeNewswire
News headline image
Updates: HRMY, MELI, SWAV ↗
​​​​​​​Another day, another slew of quarterly update reports for our followed stocks. 
Via Talk Markets
News headline image
Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript ↗
HRMY earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From Harmony Biosciences
Via GlobeNewswire
News headline image
The 3 Most Undervalued Small-Cap Stocks to Buy in February 2024 ↗
Small-cap stocks are the first ones to rally on a new business cycle, such as the business cycle starting recently. 
Via InvestorPlace
News headline image
The 3 Most Undervalued Russell 2000 Stocks to Buy in February 2024 ↗
Although the high-flying entities still capture Wall Street’s attention, astute investors should look to undervalued Russell 2000 stocks. 
Via InvestorPlace
News headline image
NASDAQ:HRMY: good value for what you're paying. ↗
In a market where value is scarce, HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
Investors should take notice of NASDAQ:HRMY—it offers a great deal for the fundamentals it presents. ↗
Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
News headline image
Why Harmony Biosciences Stock Got Slammed Today ↗
The commercial-stage company was dinged by a bearish new take from a researcher. 
Via The Motley Fool
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.